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ABSTRACT
Introduction- Gynecologic cancers contribute to a significant degree of morbidity and mortality in the female population within the United States.  These cancers, classified as endometrial, ovarian, cervical, vaginal and vulvar have distinct risk factors, prevention strategies, symptomatologies, and treatment courses. As a result, the diverse nature of gynecologic cancer presents unique challenges to public health.  
The Division of Gynecologic Oncology at Magee Womens Hospital (MWH) has developed the Gynecologic Oncology Research Database (GORDy), a biorepository, which stores patient information and biospecimens (malignant and benign) for research from patients undergoing gynecologic surgery.  To date, no studies have compared the characteristics of women within the database to those women within the total gynecologic cancer population at MWH.  
Methods- This study reviews participants and non-participants diagnosed with a gynecologic cancer between January 1, 2008 and December 31, 2011.  Demographic information, reproductive history, and disease factors were assessed between the patients using the two sample t-test, chi-square test of independence or the Fisher’s Exact test as appropriate. Cox proportional-hazards regression and logistic regression analyses were performed.
Results- In the study period, 2,144 women were diagnosed with a primary gynecologic cancer.  468 women participated in the biorepository (269 endometrial, 154 ovarian, and 45 cervical, vulvar, vaginal cancer patients).  Participation increased annually, while incidence remained stable in the population.  Participants tended to be older (p=0.0029), postmenopausal (p=0.0445) and white (p=0.0034) compared to non-participants.  Endometrial participants tended to have a higher body mass index (p=0.0931) and were more likely to be white (p=0.0010).  Ovarian cancer participants tended to be older (p=0.0471).  No significant differences were seen in the cervical, vulvar, vaginal cancer group.  Kaplan-Meier analysis showed no differences in disease progression and survival among all groups.  
Conclusions- Though participants tended to be older, postmenopausal and white they were similar to the non-participants in a number of social and clinical characteristics that normally confound studies.  This analysis demonstrates that researchers should assess the criteria used for patient recruitment, particularly age, BMI and race.  Increasing patient participation in the biorepository and data bank will increase representativeness and provide researchers with a robust collection of samples for future research projects.  
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1.0 	INTRODUCTION AND BACKGROUND
The burden of gynecologic malignancies is a significant public health problem.  Gynecologic cancers in the United States contribute to a considerable degree of morbidity and mortality of the female population.  The National Program for Cancer Registries ranks the incidence for uterine and ovarian cancer among the top ten for cancer sites in women.  In 2009, 84,155 women were diagnosed with a gynecologic cancer, and in the same year, 27,813 women died from a gynecologic cancer (U.S. Cancer Statistics Working Group, 2013).   Each type of gynecologic cancer has different risk factors, symptomatology, and treatment courses.  Furthermore, primary prevention measures and screening practices are not currently available for all gynecologic cancers. As a result, gynecologic cancers present unique challenges to public health in terms of morbidity, mortality, and prevention.  
1.1	Gynecologic Cancers
Gynecologic cancers can be classified into five main types:  endometrial (uterine), ovarian, cervical, vaginal, and vulvar.  

1.1.1	Endometrial Cancer
Endometrial cancer is the most common gynecologic malignancy.  Estimates from the American Cancer Society for 2013 predict that approximately 49,560 women will be diagnosed, and 8,190 women will die from the disease annually (ACS, 2012a).  The American Cancer Society reports that although the incidence of endometrial cancer has remained stable within the white population since 2004, there has been an increase in incidence among black women by 1.9% per year (ACS, 2012b).  A diagnosis of endometrial cancer does have a favorable prognosis if detected in the earlier stages of the disease.  Though survival declines with age, 1-year and 5-year survival rates are 92% and 82% (ACS, 2012a).  Studies have found that survival rates for endometrial cancers are lower for black women compared to white women across all age groups (Kosary, 2007a).  
Endometrial cancers can be subdivided into two distinct histologies. Type I endometrial cancers have endometrioid histology, while Type II indicates non-endometrioid which includes serous and clear cell histologies.  Type I cancers typically have a favorable prognosis, while the prognosis of Type II cancers are often less favorable (Plataniotis and Castiglione, 2010).  The causes of endometrial cancers are still largely unknown.  Factors affecting estrogen levels, like obesity (ACS, 2012a), early age at menarche, late menopause, nulliparity, and infertility have been associated with increased risk of endometrial cancer (Purdie and Green, 2001).  Pregnancy, the use of oral contraceptives, and a healthy lifestyle of proper diet and exercise have been shown to have a protective effect against endometrial cancer (Purdie and Green, 2001; ACS, 2012a).  Currently, there are no screening methods for this cancer.  Patients typically present to physicians with symptomatology including abnormal bleeding and/or pelvic pain.  Upon confirmatory diagnosis through tissue sampling, standard treatment of this cancer can include surgery, hormone therapy, and radiation.  Chemotherapeutic interventions are available as another treatment option. 
1.1.2	Ovarian Cancer
Ovarian cancer is the second most common gynecologic cancer; ranking fifth in cancer deaths in women (ACS, 2011).  The high mortality of ovarian cancer can often be attributed to delayed diagnosis. Ovarian cancer has little to no symptoms in the early stages of the disease.  Some woman may experience non-specific symptoms such as bloating, pelvic/abdominal pain, or urinary urgency/frequency for a period of time prior to diagnosis (ACS, 2012b).  The incidence of ovarian cancer in 2009 was reported to be 20,460 cases, and in the same year 14,436 women died of the disease (U.S. Cancer Statistics Working Group, 2013).  Survival rates for ovarian cancer also decline with age, with a disparity in survival among the black population across all age groups (Kosary, 2007b).    The 1-year and 5-year survival rates are 75% and 44%, respectively (ACS, 2012a).  
Established risk factors of ovarian cancer include age, positive family history, and nulliparity (Permuth-Wey and Sellers, 2009).  Positive family confers a greater risk to individuals.  As with breast cancer, mutations in the BRCA1 and BRCA2 genes have been shown to increase risk of inherited ovarian cancers (ACS, 2011). BRCA1 mutations have a lifetime ovarian cancer risk between 35%-70%, while the BRCA2 mutation has a risk within 10%-30% (ACS, 2011).  In instances of positive family history, prophylactic oophorectomy can decrease this risk (Permuth-Wey and Sellers, 2009).  Other possible risk factors for ovarian cancer include hormone replacement therapy (estrogen only) (ACS, 2012b) and lifestyle factors such as smoking, alcohol consumption, and obesity (related to improper diet and lack of exercise) (Permuth-Wey and Sellers, 2009).  Similar to endometrial cancer, pregnancy, the use of oral contraceptives, and a healthy lifestyle have been shown to have a protective effect against ovarian cancer (Permuth-Wey and Sellers, 2009; ACS 2012a).  Standard treatment options for ovarian cancer include surgery and chemotherapy.

1.1.3	Cervical Cancer
Cervical cancer is the only gynecologic cancer with a screening procedure: the Papanicolaou (PAP) test.  In addition to screening, immunization against human papillomavirus (HPV) offers a primary prevention method.  The vaccine protects individuals from certain strains of HPV known to cause cervical cancer (CDC, 2013).  The HPV vaccine also offers protection against cancers of the vagina and vulva (CDC, 2013).  Prevention and early detection contribute to the lower mortality of cervical cancer.   Estimates from the American Cancer Society for 2013 predict that approximately 12,340 women will be diagnosed, and 4,030 women will die from the disease (ACS, 2012c).  The American Cancer Society reports the 1-year and 5-year survival rates for cervical cancers to be 87% and 69%, with a 5-year survival rate of 91% for patients with localized disease (ACS, 2012b).  Similarly, survival rates for cervical cancers are lower for black women compared to white women, with the exception of women over 70 (Kosary, 2007c).  
The association between cervical cancer and HPV infection is well established.  Other risk factors for cervical cancer include smoking, high parity, use of oral contraceptives, an unhealthy diet, and other sexually transmitted infections (Franco, 2003).  Cervical cancer is typically treated with local surgery when detected early.  For invasive cases, surgery, radiation, and chemotherapy are available treatment options.
1.1.4	Vulvar and Vaginal Cancers
Vulvar and vaginal cancers are both considered to be rare among gynecologic cancers.  The American Cancer Society estimates that 4,700 women will be diagnosed, and 990 women will die of vulvar cancer this year (ACS, 2013b).  The National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) reports only minor differences in 5-survival existing between white and black women with vulvar cancer (Kosary, 2007e).  Estimates from the American Cancer Society for 2013 predict that approximately 2,890 women will be diagnosed, and 840 women will die from vaginal cancers (ACS, 2013a).  Though only minor differences exist in survival rates for vulvar cancers, the disparity between white and black women remains in the 5-year survival rates for vaginal cancers (Kosary, 2007d).  
Vulvar and vaginal cancers have similar risk factors to cervical cancer, including the association with HPV infection (Edwards, 1996; Wu, 2008).  Treatment options for these cancers are also similar to cervical cancer.  Local surgeries are used to treat earlier stages, while surgery, radiation and chemotherapy can be used for invasive cases.

1.2	The Gynecologic Cancer Repository and Data Bank
Biorepositories store biospecimens for future investigations.  Additionally, patient data including demographic, social, and medical information are often collected from the research participant.  The National Cancer Institute’s Biorepositories and Biospecimen Research Branch states with molecular-based research, biorepositories can aid in the development of new diagnostics and therapies to improve patient outcome (National Cancer Institute, 2013). 
Biorepositories are an invaluable resource to researchers in understanding the etiology, progression, and treatment of cancers.  The Gynecologic Oncology Research Database (GORDy) was developed at University of Pittsburgh Medical Center Magee-Womens Hospital (MWH), Department of Gynecologic Oncology with the objective to provide researchers with biological specimens for research involving both benign and malignant gynecologic conditions.  This ongoing effort to collect biospecimens and data has been approved by the University of Pittsburgh’s Institutional Review Board.  Specimens include but are not limited to serum, plasma, malignant gynecologic tumors, benign tumors, ascites, and healthy gynecologic tissues.  Patient information from medical records including medical history, family medical history, medication use, social/lifestyle information, surgery reports, diagnoses, and treatment regimens is also collected.  Since its inception in 2006, 1556 women (including both benign and malignant cases) have consented to participate.  Though GORDy was designed to collect biospecimens, data, and clinical outcomes from patients with all gynecologic cancers, there has been an emphasis placed on the collection of endometrial and ovarian specimens because of investigator research interests at MWH.  
Women undergoing surgery for a gynecologic cancer, benign gynecologic condition or prophylactic oophorectomy are eligible to participate in the repository.  Tissue samples are collected at the time of surgery, and blood samples are collected at the time of consent, at time of surgery, and at each follow up visit thereafter.  Biologic samples are collected if patient has recurrent disease.  Patients are recruited from multiple sites throughout the University of Pittsburgh Medical Center (UPMC) hospital system; however the bulk of cases are obtained at MWH.    
To date, no studies have been performed to compare women within the repository to those women within the total gynecologic cancer population at MWH.  Determining the composition of the patient population within the biorepository will validate future studies and ensure the generalizability of those results.  This study will show if any gaps exist in patient recruitment to the biorepository and data bank.  If the patient populations differ significantly, efforts can be made to either target patient recruitment to increase numbers of the underrepresented populations or to determine what can be done to motivate specific patient populations to participate.  This work has great potential to ensure that GORDy can be used for high quality studies of gynecologic cancers in the future.  




Women diagnosed with an incident, primary gynecologic cancer between January 1, 2008 and December 31, 2011 were chosen for this study.  These years correspond with the time when recruitment procedures were standardized and completed: a total of 1202 benign and malignant cases were enrolled over the four year period.  In this study, only malignant cases were included because of the nature of data availability in the UPMC Network Cancer Registry.  A total of 2,144 patients were analyzed (468 biorepository participants and 1676 non-participants).  The total number of patients approached for participation in the biorepository during this time period is unknown.    Primary cancers were classified into three groups based on pathology as indicated in pathology reports: endometrial, ovarian, and a combined group of cervical, vulvar, and vaginal cancers.  Vaginal, vulvar, and cervical cancers were grouped for analysis because of similar epidemiology and relative rarity of these cancers.  Total sample size per group is reported, inclusive of participants and non-participants: endometrial (n=1158), ovarian (n=517), and a combined group for cervical, vulvar and vaginal cancers (n=469).  

2.2	data collection
For this study, all data were obtained through the UPMC Network Cancer Registry to ensure standardized collection and reporting of variables for analyses. Cases with reportable cancer diagnoses are captured through Hospital Information Systems (electronic medical records), Pathology Systems, and Radiation Oncology.  All data is standardized according to the North American Association of Central Cancer Registries data standards (UPMC Cancer Centers Registry Information Services, 2013). Though the Network Cancer Registry collects data from all UPMC facilities, this study reviewed only women diagnosed at UPMC Magee-Womens Hospital, Pittsburgh, PA.

2.3	Histology codes
The UPMC Network Cancer Registry codes all histological data using the International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3).  SEER literature was referenced for grouping histological categories (SEER, 2006).  Due to the smaller sample size of this study, not all of the SEER histological categories of disease were represented.  Unspecified differentiations were classified as ICD-O-3 codes 8000-8003.
In this study, endometrial cancer was grouped by its two distinct histological subtypes: Type I and Type II.  Type I ICD-O-3 codes included 8140, 8380-8383, 8480, 8560, 8570 and Type II codes included 8310, 8323, 8441, 8460-8461.  All codes outside of these were classified as “other specified”.
The four main differentiations of ovarian cancers include clear cell (ICD-O-3 code 8310), endometrioid (ICD-O-3 code 8380), mucinous (ICD-O-3 codes 8470-8473, 8480) and serous (ICD-O-3 codes 8441-8442, 8460-8462).  All codes outside of these were classified as “other specified”.
Cervical cancer differentiations fall into two main categories, squamous (approximately 80% of cases) and adenocarcinoma (approximately 20% of cases) (Gattoc et al, 2011).  ICD-O-3 codes 8050-8083 were classified as squamous and 8140-8384 were classified as adenocarcinoma.  All codes outside of these were classified as “other specified”.

2.4	Stages
All tumors are classified based on the International Federation of Gynecology and Obstetrics (FIGO) staging system: Stage 0 refers to carcinoma in situ, specifically intraepithial neoplasia grade III (Odicino, 2008); Stage I describes a tumor confined to the organ of origin; Stage II describes a cancer that has advanced locally; Stage III extensive involvement; and Stage IV describes metastatic disease (Pecorelli, 2006). In this study, cancers of the cervix, vulva and vagina were assessed at Stages 0-IV; endometrial and ovarian cancers were assessed at Stages I-IV.  

2.5	Statistical Analysis
Continuous variables (age and BMI) were first compared using a two-sample t-test.  Unknown or missing variables were excluded from statistical analysis; missing data did not exclude patients from analysis.  All variables were then categorized for further analysis.  The chi-square test of independence was performed to compare categorical variables.  For variables that had lower than expected values (<5), the chi-square test would be considered invalid.  Under these circumstances, the Fisher’s Exact test was utilized.  A p-value < 0.05 was considered significant.  Stratified Odds Ratios (OR) and 95% confidence intervals were calculated for all patient and disease variables.
Time of diagnosis to time of recurrence was compared between all primary cancer classifications for participants and non-participants using the Kaplan-Meier method.  The log-rank test was used to determine if differences in recurrence existed between the two groups.
To assess survival, time of diagnosis to date of last contact was compared between all primary cancer classifications for participants and non-participants using the Kaplan-Meier method.  The Cancer Registry reports the date of last contact as the date of death when the patient vital status is recorded as “deceased”.  The log-rank test was used to determine if differences in survival exist between the participants and non-participants in each gynecologic cancer group.
Cox proportional-hazards regression was used to determine which variables contributed significantly to mortality, after adjusting for all other covariates, for each primary cancer groups.  A univariate approach was first used to determine which variables would be tested in the model using a p-value ≤ 0.1.  The variable indicating participation in the biorepository and significant variables were included in the multivariate analysis.  Though participation was not found to be significant in any of the cancer groups, the participant indicator variable was included in each of the models to control for participation in the biorepository.  Covariates with a p-value ≤ 0.05 were kept in the final model.  Interactions between covariates were tested; none were found to be significant in any of the primary cancer groups.
Logistic regression was performed to determine which variables contributed significantly to participation in the repository after controlling for all other covariates.  As with the Cox proportional-hazards regression, the univariate approach was first used to determine which variables would be tested in the model using a p-value ≤ 0.1.  In the multivariate analysis, only covariates with a p-value ≤ 0.05 were kept in the final model.  No significant interactions were observed.  All data was analyzed using SAS (version 9.3, SAS Institute Inc, Cary, NC, USA).
3.0 	Results
3.1	All Gynecologic Cancers
Between January 1, 2008 and December 31, 2011 2,144 women were diagnosed with a primary gynecologic cancer at MWH.  Of these cases, 468 women consented for participation in the biorepository.  Analysis showed that women in both the participant and non-participant groups were similar on a number of factors including BMI, smoking status, alcohol use, pregnancy and birth histories, family cancer history, marital status, grade, recurrence and vital status.  The data on patient demographic, social and reproductive characteristics for all cancers are presented in Table 1.  
Table 1. Demographic, social and reproductive characteristics, all gynecologic cancers

	All Gynecologic Cancers (2144)
	Participants (468)	Non-Participants (1676)	 	 
	N(%)	N(%)	OR (95%CI)	                           p-value (χ2)
Age	 			0.0010
≤44	48 (10.3)	300 (17.9)	0.54 (0.38-0.77)	 
45-54	105 (22.4)	320 (19.1)	1.10 (0.38-1.46)
55-64	150 (32.1)	503 (30.0)	1.0 (ref)
≥65	164 (35.0)	553 (33.0)	0.99 (0.77-1.28)
 	 			 
Race	 			             0.0034
White	457 (97.6)	1573 (93.9)	1.0 (ref)	 
Black	10 (2.1)	88 (5.3)	0.39 (0.20-0.76)
Other	0 (0.0)	11 (0.7)		 
 	 			 
BMI	 			                         0.0922
Below 18.5	58 (12.4)	269 (16.1)	0.88 (0.60-1.28)
18.5-24.9 (Normal)	79 (16.9)	322 (19.2)	1.0 (ref)	 
25.0-29.9 (Overweight)	106 (22.6)	364 (21.7)	1.19 (0.86-1.65)
30.0-39.9 (Obese)	144 (30.8)	453 (27.0)	1.30 (0.95-1.77)
>40 (Morbidly Obese)	79 (16.9)	246 (14.7)	1.31 (0.92-1.86)
 	 			 
Postmenopausal	 			                  0.0445
No	111 (23.7)	464 (27.7)	1.0 (ref)	 
Yes	309 (66.0)	1007 (60.1)	1.28 (1.01-1.64)
 	 			 
Smoking Status	 			                   0.0882
Never	324 (69.2)	1100 (65.6)	1.0 (ref)	 
Ever	131 (28.0)	542 (32.3)	0.82 (0.65-1.03)
 	 			 
Alcohol use	 			             0.4008
Never	439 (93.8)	1542 (92.0)	1.0 (ref)	 
Ever	19 (4.1)	83 (5.0)	0.80 (0.48-1.34)
 				
Full-Term Births	 			              0.4578
0	103 (22.0)	408 (24.3)	1.0 (ref)	 
1	75 (16.0)	225 (13.4)	1.32 (0.94-1.85)
2	127 (27.1)	298 (17.8)	1.69 (1.25-2.28)
3+	122 (26.1)	442 (26.4)	1.09 (0.81-1.47)
 	 			 
Pregnancy History 	 			              0.2698
0	89 (19.0)	358 (21.4)	1.0 (ref)	 
1	72 (15.4)	215 (12.8)	1.35 (0.95-1.92)
2	118 (25.2)	375 (22.4)	1.27 (0.93-1.73)
3+	150 (32.1)	554 (33.1)	1.09 (0.81-1.46)
 	 			 
Parity	 			                 0.2114
Nulliparous	103 (22.0)	408 (24.3)	1.0 (ref)	 
Ever parous	324 (69.2)	1095 (65.3)	1.17 (0.91-1.50)
 	 			 
Positive Family Cancer History (any)	 			              0.2961
No	156 (33.3)	578 (34.2)	1.0 (ref)	 
Yes	286 (61.1)	942 (56.2)	1.12 (0.90-1.40)
 	 			 
Marital Status	 			                0.2446
Single	85 (18.2)	360 (21.5)	1.0 (ref)	 
Married	276 (59.0)	906 (54.1)	1.29 (0.98-1.69)
Divorced	44 (9.4)	179 (10.7)	1.04 (0.69-1.56)
Widowed	63 (13.5)	216 (12.9)	1.24 (0.86-1.78)
The two sample t-test analysis showed that participants (mean=60.2, 95% confidence limits=59.1-61.3) were slightly older than non-participants (mean=58.0, 95% confidence limits=57.3-58.7) (p=0.0029).  BMI did not significantly differ between the participant and non-participant groups (mean=32.7, 95% confidence limits=31.8-33.6 vs. mean=31.9, 95% confidence limits=31.4-32.4; p=0.1255).  When comparing the total gynecologic cancer population, chi-square analysis showed that participants were older, predominantly white, and postmenopausal (p=0.0010, p=0.0034 and p=0.0445, respectively).  The biorepository had a higher percentage of women in the each of the following age categories: 45-54 (105 (22.4%) vs. 320 (19.1%)), 55-64 (150 (32.1%) vs. 503 (30.0%)), and ≥65 (164 (35.0%) vs. 553 (33.0%)).  Less women tended to participate in the ≤44 age category (48 (10.3%) vs. 300 (17.9%)).  This increased age among participants corresponds to the differences in menopausal status; 309 (66.0%) of participants were postmenopausal vs. 1007 (60.1%) of non-participants.  The odds of postmenopausal women participating in the biorepository were 1.28 times higher than women who have not reached menopause.  Black women were 61% less likely to participate in the biorepository compared to white women.  Despite the difference between white and black participation, the percent differences within the groups were found to be similar.  Among black women, there was a 3.2% difference between the participants and non-participants (10 (2.1%) vs. 88 (5.3%)).  Among white women, there was a 3.7% difference between the participants and non-participants (457 (97.6%) vs. 1573 (93.9%)).
Table 2 shows the diagnosis and disease cancer characteristics for cases.  Between participants and non-participants, year of diagnosis, primary location, and stage were all found to be significantly different (p=<0.001).  The odds of participation in the biorepository increased each year.  With respect to differences in primary location of the gynecologic tumor, participants were more likely to have endometrial or ovarian cancers.    Stages of cancer did differ significantly; participants were 82% less likely than non-participants to have Stage 0 cancer (10 (2.1%) vs. 175 (10.4%)).  59.8% (280) of participants were diagnosed with a Stage I cancer compared to 51.7% (363) of non-participants.
Table 2. Diagnosis and disease characteristics, all gynecologic cancers
	All Gynecologic Cancers (2144)
	Participants (468)	Non-Participants (1676)	 	 
	N(%)	N(%)	OR (95%CI)	p-value (χ2)
Year of Diagnosis	 			                <.0001
2008	83 (17.7)	424 (25.3)	1.0 (ref)	 
2009	98 (20.9)	449 (26.8)	1.11 (0.80-1.55)
2010	128 (27.4)	440 (26.3)	1.49 (1.08-2.04)
2011	159 (34.0)	363 (21.7)	2.24 (1.64-3.05)
 	 			 
Primary Location	 			                          <.0001
Endometrial	269 (57.5)	889 (53.0)	1.0 (ref)	 
Ovarian	154 (32.9)	363 (21.7)	1.40 (1.11-1.77)
Cervical	21 (4.5)	170 (10.1)	0.41 (0.25-0.66)
Vulvar	24 (5.1)	229 (13.7)	0.35 (0.22-0.54)
Vaginal	0 (0.0)	25 (1.5)		 
	 			 
Stage	 			                          <.0001
0	10 (2.1)	175 (10.4)	0.18 (0.09-0.34)
I	280 (59.8)	866 (51.7)	1.0 (ref)	 
II	30 (6.4)	140 (8.4)	0.66 (0.44-1.01)
III	96 (20.5)	307 (18.3)	0.97 (0.74-1.26)
IV	26 (5.6)	96 (5.7)	0.84 (0.53-1.32)
	 			 
Grade	 			0.1792
1	143 (30.6)	420 (25.1)	1.0 (ref)	 
2	105 (22.4)	408 (24.3)	0.76 (0.34-1.70)
3	135 (28.8)	422 (25.2)	0.94 (0.42-2.10)
4	19 (4.1)	47 (2.8)	1.19 (0.46-3.06)
 	 			 
Recurrence	 			0.6462
No 	419 (89.5)	1469 (87.6)	1.0 (ref)	 
Yes	45 (9.6)	148 (83.8)	1.07 (0.66-1.72)
 	 			 
Vital Status	 			0.5161
Alive	403 (86.1)	1423 (84.9)	1.0 (ref)	 
Dead	65 (13.9)	253 (15.1)	0.91 (0.59-1.40)

Kaplan-Meier analysis showed that recurrent cancers were not significantly different between participants and non-participants in all cancer types (endometrial, ovarian and the cervical, vulvar, and vaginal cancer group).  Similarly, no differences in survival were seen between the participants and non-participants in each cancer group. 

3.2	Endometrial Cancer





Table 3. Demographic, social and reproductive characteristics, endometrial
	Endometrial (N=1158)
	Participant (269) N(%)	Non-Participant (889) N(%)	OR (95%CI)	p-value (χ2 or Fisher's Exact*)
Age	 			    0.6436
≤44	17 (6.3)	49 (5.5)	1.27 (0.70-2.30)	 
45-54	54 (20.1)	157 (17.7)	1.26 (0.86-1.84)	 
55-64	96 (35.7)	351 (39.5)	1.0 (ref)	 




White	263 (97.8)	831 (93.5)	1.0 (ref)	 
Black	5 (1.9)	52 (5.8)	0.30 (0.12-.077)	 
Other	0 (0.0)	5 (0.6)		 
 	 			 
BMI	 			      0.001
Below 18.5	22 (8.2)	139 (15.6)	0.86 (0.46-1.62)	 
18.5-24.9 (Normal)	23 (8.6)	125 (14.1)	1.0 (ref)	 
25.0-29.9 (Overweight)	61 (22.7)	163 (18.3)	2.03 (1.19-3.47)	 
30.0-39.9 (Obese)	96 (35.7)	270 (30.4)	1.93 (1.17-3.19)	 
>40 (Morbidly Obese)	67 (24.9)	186 (20.9)	1.96 (1.96-3.31)	 
 	 			 
Postmenopausal	 			    0.2615
No	58 (21.6)	157 (17.7)	1.0 (ref)	 
Yes	192 (71.4)	632 (71.1)	0.82 (0.58-1.16)	 
 	 			 
Smoking Status	 			    0.9927
Never	195 (72.5)	650 (73.1)	1.0 (ref)	 
Ever	68 (25.3)	227 (25.5)	1.00 (0.73-1.37)	 
 	 			 
Alcohol use	 			    0.3008
Never	257 (95.5)	835 (93.9)	1.0 (ref)	 
Ever	8 (3.0)	39 (4.4)	0.67 (0.14-3.08)	 
 				
Full-Term Births	 			      0.348
0	62 (23.0)	214 (24.1)	1.0 (ref)	 
1	34 (12.6)	136 (15.3)	0.86 (0.54-1.38)	 
2	79 (29.4)	214 (24.1)	1.27 (0.87-1.87)	 
3+	78 (29.0)	241 (27.1)	1.12 (0.76-1.64)	 
 	 			 
Pregnancy History 	 			    0.7793
0	54 (20.1)	196 (22.0)	1.0 (ref)	 
1	36 (13.4)	105 (11.8)	1.24 (0.77-2.02)	 
2	69 (25.7)	210 (23.6)	1.19 (0.79-1.79)	 
3+	95 (35.3)	294 (33.1)	1.17 (0.80-1.71)	 
 	 			 
Parity	 			    0.5115
Nulliparous	62 (23.0)	214 (24.1)	1.0 (ref)	 
Ever parous	191 (71.0 )	591 (66.5)	1.12 (0.80-1.55)	 
 	 			 
Positive Family Cancer History (any)	 			    0.6825
No	90 (33.5)	305 (34.3)	1.0 (ref)	 
Yes	165 (61.3)	526 (59.2)	1.06 (0.79-1.43)	 
 	 			 
Marital Status	 			      0.805
Single	49 (18.2)	172 (19.3)	1.0 (ref)	 
Married	151 (56.1)	501 (56.4)	1.06 (0.73-1.53)	 
Divorced	25 (9.3)	86 (9.7)	1.02 (0.59-1.76)	 
Widowed	44 (16.4)	124 (13.9)	1.25 (0.78-1.99)	 

The two sample t-test analysis showed that participants (mean=61.2, 95% confidence limits=60.5-63.2) and non-participants (mean=61.6, 95% confidence limits=61.1-62.5) do not differ in age (p=0.9011).  Participants tended to have a higher BMI than non-participants, however this did not reach statistical significance when analyzed as a continuous variable (mean=35.5, 95% confidence limits=34.3-36.7 vs. mean=34.3, 95% confidence limits=33.5-35.0; p=0.0931).  Through chi-square analysis, BMI was significantly different between the BMI categories: BMI<18.5, normal, overweight, obese, and morbidly obese (p=0.001).  Participants had roughly a 2 times higher odds of being overweight, obese and morbidly obese compared to participants with a normal BMI.  Fisher’s Exact test showed that race differed significantly between the participant and non-participant women (p=0.0095).  Black women were 70% less likely to participate in the biorepository compared to white women.    
Table 4 shows the diagnosis and disease characteristics for endometrial cancer cases. Year of diagnosis was found to be significantly different (p=<.0001).  Participation increased annually, while the incidence in the non-participant population remained stable across time.  Vital status differed significantly between the participant and non-participant groups (p=0.0424). 
Table 4. Diagnosis and disease characteristics, endometrial
	Endometrial (1158)
	Participants (269)	Non-Participants (889)		 
	N(%)	N(%)	OR (95%CI)	p-value (χ2 or Fisher's Exact*)
Year of Diagnosis	 			               <.0001
2008	38 (14.1)	238 (26.8)	1.0 (ref)	 
2009	53 (19.7)	254 (28.6)	1.31 (0.83-2.05)	 
2010	63 (23.4)	223 (25.1)	1.77 (1.14-2.75)	 
2011	115 (42.8)	174 (19.6)	4.14 (2.73-6.27)	 
 	 			 
Stage	 			                 0.065
0	-	-	-	
I	195 (72.5)	580 (65.2)	1.0 (ref)	 
II	18 (6.7)	77 (8.7)	0.70 (0.41-1.19)	 
III	35 (13.0)	122 (13.7)	0.85 (0.57-1.28)	 
IV	5 (1.9)	44 (4.9)	0.34 (0.13-0.86)	 
 	 			 
Grade	 			               0.2671
1	111 (41.3)	308 (34.6)	1.0 (ref)	 
2	84 (31.2)	293 (33.0)	0.80 (0.57-1.10)	 
3	57 (21.2)	222 (25.0)	0.71 (0.50-1.02)	 
4	7 (2.6)	20 (2.2)	0.97 (0.40-2.36)	 
 	 			 
Recurrence	 			               0.6083
No 	249(92.6)	805 (90.6)	1.0 (ref)	 
Yes	18 (6.7)	67 (7.5)	0.87 (0.51-1.49)	 
 	 			 
Vital Status	 			               0.0424
Alive	247 (91.8)	776 (87.3)	1.0 (ref)	 
Dead	22 (8.2)	113 (12.7)	0.61 (0.38-0.99)	 
				
Histology	 			             0.7297*
Type 1	194 (72.1)	615 (69.2)	1.0 (ref)	 
Type 2	46 (17.1)	169 (19.0)	0.86 (0.60-1.24)	 
All other specified	29 (10.8)	101 (11.4)	0.91 (0.58-1.42)	 
Unspecified	0 (0.0)	4 (0.4)	-	 









Table 5. Predictors of endometrial cancer mortality






















Table 6. Multivariate logistic regression endometrial results: odds ratios
Variable	Odds Ratio (95% CI)
BMI		 
NormalOverweight (BMI 25.0-29.9) 	1.0 (ref)2.06 (1.21-3.52)
Obese/Morbidly Obese (BMI ≥ 30.0)	1.95 (1.21-3.15)







A total of 517 cases were analyzed (154 participants and 363 non-participants).  Analysis showed that ovarian cancer patients in both the participant and non-participant groups were similar on a number of factors including race, BMI, postmenopausal status, smoking status, alcohol use, pregnancy and birth histories, family cancer history, marital status, year of diagnosis, stage, grade, recurrence and vital status.  The data on patient demographic, social and reproductive characteristics for ovarian cancer are presented in Table 7.  
Table 7. Demographic, social and reproductive characteristics, ovarian
	Ovarian (517)
	Participant (154) N(%)	Non-Participant (363) N(%)	OR (95%CI)	p-value (χ2 or Fisher's Exact*)
Age	 			          0.0414
≤44	17 (11.0)	79 (21.8)	0.44(0.23-0.83)	 
45-54	41 (26.6)	85 (23.4)	0.99 (0.59-1.66)	 
55-64	43 (27.9)	88 (24.2)	1.0 (ref)	 
≥65	53 (34.4)	111 (30.6)	0.98 (0.60-1.60)	 
 	 			 
Race	 			        0.5917*
White	151 (98.1)	348 (95.9)	1.0 (ref)	 
Black	3 (1.9)	14 (3.9)	0.49 (0.14-1.74)	 
Other	0 (0.0)	1 (0.3)	0	 
 	 			 
BMI	 			          0.1907
Below 18.5	28 (18.2)	53 (14.6)	1.09 (0.61-1.94)	 
18.5-24.9 (Normal)	46 (29.9)	95 (26.2)	1.0 (ref)	 
25.0-29.9 (Overweight)	31 (20.1)	106 (29.2)	0.60 (0.35-1.76)	 
30.0-39.9 (Obese)	39 (25.3)	77 (21.2)	1.05 (0.62-1.76)	 
>40 (Morbidly Obese)	9 (5.8)	28 (7.7)	0.66 (0.29-1.52)	 
 	 			 
Postmenopausal	 			          0.1279
No	35 (22.7)	106 (29.2)	1.0 (ref)	 
Yes	97 (63.0)	207 (57.0)	1.42 (0.90-2.23)	 
 	 			 
Smoking Status	 			          0.4794
Never	106 (68.8)	245 (67.5)	1.0 (ref)	 
Ever	42 (27.3)	113 (31.1)	0.86 (0.56-1.31)	 
 	 			 
Alcohol use	 			          0.4694
Never	140 (90.9)	339 (93.4)	1.0 (ref)	 
Ever	9 (5.8)	16 (4.4)	1.36 (0.59-3.16)	 
 				
Full-Term Births	 			          0.2206
0	34 (22.1)	100 (27.5)	1.0 (ref)	 
1	31 (20.1)	53 (14.6)	1.72 (0.95-3.10)	 
2	40 (26.0)	82 (22.6)	1.43 (0.83-2.47)	 
3+	33 (21.4)	91 (25.1)	1.07 (0.61-1.86)	 
 	 			 
Pregnancy History 	 			          0.2262
0	30 (19.5)	85 (23.4)	1.0 (ref)	 
1	28(18.2)	55 (15.2)	1.44 (0.78-2.67)	 
2	40 (26.0)	71 (19.6)	1.60 (0.90-2.82)	 
3+	41 (26.6)	115 (31.7)	1.01 (0.58-1.75)	 
 	 			 
Parity	 			          0.1896
Nulliparous	34 (22.1)	100 (27.5)	1.0 (ref)	 
Ever parous	104 (67.5)	226 (62.3)	1.35 (0.86-2.13)	 
 	 			 
Positive Family Cancer History (any)	 			          0.2033
No	49 (31.8)	133 (36.6)	0.77 (0.51-1.15)	 
Yes	96 (62.3)	200 (55.1)	1.0 (ref)	 
 	 			 
Marital Status	 			          0.2499
Single	25 (16.2)	76 (20.9)	1.0 (ref)	 
Married	101 (65.6)	205 (56.5)	1.50 (0.90-2.50)	 
Divorced	14 (9.1)	31 (8.5)	1.37 (0.63-2.98)	 
Widowed	14 (9.1)	47 (12.9)	0.91 (0.43-1.91)	 

The two sample t-test analysis showed that participants (mean=59.0, 95% confidence limits=56.9-61.0) were older than non-participants (mean=56.0, 95% confidence limits=54.4-57.6) (p=0.0367).  BMI did not significantly differ between the participant and non-participant groups (mean=28.4, 95% confidence limits=26.9-29.8 vs. mean=29.0, 95% confidence limits=28.1-29.9; p=0.4400).  In chi-square analysis, the age categorizations were statistically significant between the participant and non-participant groups (p=0.0414).  The biorepository had nearly half as much women in the ≤44 age category (17 (11.0%) vs. 79 (21.8%)).  The other categories had a higher representation in the participant group: 45-54 (41 (26.6%) vs. 85 (23.4%)), 55-64 (43 (27.9%) vs. 88 (24.2%)), and ≥65 (53 (34.4%) vs. 111 (30.6%)).


















Year of Diagnosis	 			             0.3471
2008	32 (20.8)	92 (25.3)	1.0 (ref)	 
2009	34 (22.1)	92 (25.3)	106 (0.61-1.86)	 
2010	52 (33.8)	97 (26.7)	1.54 (0.91-2.60)	 
2011	36 (23.4)	82 (22.6)	1.26 (0.72-2.21)	 
 	 			 
Stage	 			             0.4378
0	-	-	-	
I	64 (41.6)	144 (39.7)	1.0 (ref)	 
II	7 (4.5)	30 (8.3)	0.53 (0.22-1.26)	 
III	54 (35.1)	131 (36.1)	0.93 (0.60-1.43)	 
IV	31 (13.6)	41 (11.3)	1.15 (0.63-2.11)	 
 	 			 
Grade	 			             0.6081
1	25 (16.2)	52 (14.3)	1.0 (ref)	 
2	11 (7.1)	39 (10.7)	0.59 (0.26-1.33)	 
3	65 (42.2)	146 (40.2)	0.93 (0.53-1.62)	 
4	11 (7.1)	27 (7.4)	0.85 (0.36-1.98)	 
 	 			 
Recurrence	 			             0.3825
No 	134 (87.0)	322 (88.7)	1.0 (ref)	 
Yes	18 (11.7)	33 (9.1)	1.31 (0.71-2.41)	 
 	 			 
Vital Status	 			             0.9536
Alive	118 (76.6)	279 (76.9)	1.0 (ref)	 
Dead	36 (23.4)	84 (23.1)	1.01 (0.65-1.58)	 
Histology	 			             0.0249
Serous	80 (51.9)	161 (44.4)	1.0 (ref)	 
Clear Cell	20 (13.0)	24 (6.6)	1.68 (0.87-3.22)	 
Endometrioid	11 (7.1)	45 (12.4)	0.49 (0.24-1.00)	 
Mucinous	14 (9.1)	39 (10.7)	0.72 (0.37-1.41)	 
All other specified	20 (13.0)	70 (19.3)	0.58 (0.33-1.01)	 
Unspecified	0 (0.0)	2 (0.6)	-	 

Univariate analysis found several covariates associated with survival (p ≤ 0.1): age, BMI, stage, grade, histology, and menopausal status.  Multivariate analysis revealed that age, stage and histology were significantly associated with mortality (p ≤ 0.05) (Table 9).  No significant interactions were observed.
Table 9. Predictors of ovarian cancer mortality




















Univariate logistic regression yielded two significant variables associated with participation in the biorepository: age and histology.  In multivariate logistic regression analysis only histology remained as a significant variable in association to participation in the biorepository (Table 10, Figure 2).   
Table 10. Multivariate logistic regression ovarian results: odds ratios









3.4	Cervical, Vulvar, and Vaginal Cancers
For this group, 469 total cases were analyzed (45 participants and 424 non-participants).  This group is made up of 191 cervical cancer patients (21 participants and 170 non-participants), 253 vulvar cancer patients (24 participants and 229 non-participants), and 25 vaginal cancer patients (all non-participants).  Table 11 presents patient demographic, social and reproductive characteristics for these cancers, and Table 12 displays diagnosis and disease characteristics.  
Table 11. Demographic, social and reproductive characteristics, cervical, vulvar, and vaginal cancers

	Cervical, Vulvar, and Vaginal (469)
	Participant (45) N(%)	Non-Participant (424) N(%)	OR (95%CI)	p-value (χ2 or Fisher's Exact*)
Age	 			     0.2983
≤44	14 (31.1)	172 (40.6)	0.47 (0.20-1.10)	 
45-54	10 (22.2)	78 (18.4)	0.75 (0.30-1.87)	 
55-64	11 (24.4)	64 (15.1)	1.0 (ref)	 
≥65	10 (22.2)	110 (25.9)	0.53 (0.21-1.31)	 
 	 			 
Race	 			        1.00*
White	43 (95.6)	394 (92.9)	1.0 (ref)	 
Black	2 (4.4)	22 (5.2)	0.83 (0.19-3.66)	 
Other	0 (0)	5 (1.2)	0	 
 	 			 
BMI	 			      0.7212
Below 18.5	8 (17.8)	77 (18.2)	1.16 (0.44-3.08)	 
18.5-24.9 (Normal)	10 (22.2)	112 (26.4)	1.0 (ref)	 
25.0-29.9 (Overweight)	14 (31.1)	95 (22.4)	1.65 (0.70-3.89)	 
30.0-39.9 (Obese)	9 (20.0)	106 (25.0)	0.95 (0.37-2.43)	 
>40 (Morbidly Obese)	3 (6.7)	32 (7.5)	1.05 (0.27-4.05)	 
 	 			 
Postmenopausal	 			        0.403
No	18 (40.0)	201 (47.4)	1.0 (ref)	 
Yes	20 (44.4)	168 (39.6)	1.33 (0.68-2.60)	 
 	 			 
Smoking Status	 			      0.8103
Never	23 (51.1)	205 (48.3)	1.0 (ref)	 
Ever	21 (46.7)	202 (47.6)	0.93 (0.49-1.74)	 
 	 			 
Alcohol use	 			    0.7555*
Never	42 (93.3)	368 (86.8)	1.0 (ref)	 
Ever	2 (4.4)	28 (6.6)	0.63 (0.14-2.72)	 
 				
Full-Term Births	 			      0.4638
0	7 (15.6)	94 (22.2)	1.0 (ref)	 
1	10 (22.2)	66 (15.6)	2.03 (0.74-5.62)	 
2	8 (17.8)	102 (24.1)	1.05 (0.37-3.02)	 
3+	11 (24.4)	110 (25.9)	1.34 (0.05-3.60)	 
 	 			 
Pregnancy History 	 			      0.5871
0	5 (11.1)	77 (18.2)	1.0 (ref)	 
1	8 (17.8)	55 (12.9)	2.24 (0.70-7.22)	 
2	9 (20.0)	94 (22.2)	1.47 (0.47-4.58)	 
3+	14 (31.1)	145 (34.2)	1.49 (0.52-4.28)	 
 	 			 
Parity	 			      0.4394
Nulliparous	7 (15.6)	94 (22.2)	1.0 (ref)	 
Ever parous	29 (64.4)	278 (65.6)	1.40 (0.59-3.30)	 
 	 			 
Positive Family Cancer History (any)	 			      0.8853
No	17 (37.8)	140 (33.0)	1.0 (ref)	 
Yes	25 (55.6)	216 (50.9)	0.95 (0.50-1.83)	 
 	 			 
Marital Status	 			      0.8657
Single	11 (24.4)	112 (26.4)	1.0 (ref)	 
Married	24 (53.3)	200 (47.2)	1.22 (0.58-2.59)	 
Divorced	5 (11.1)	62 (14.6)	0.82 (0.27-2.47)	 
Widowed	5 (11.1)	45 (10.6)	1.13 (0.37-3.44)	 

Table 12. Diagnosis and disease characteristics, cervical, vulvar, and   vaginal cancers
	Cervical, Vulvar, and Vaginal (469)
	Participants (45)	Non-Participants (24)		 
	N(%)	N(%)	OR (95%CI)	p-value (χ2 or Fisher's Exact*)
Year of Diagnosis	 			0.6296
2008	13 (28.9)	94 (22.2)	1.0 (ref)	 
2009	11 (24.4)	103 (24.3)	0.77 (0.33-1.81)	 
2010	13 (28.9)	120 (28.3)	0.78 (0.35-1.77)	 
2011	8 (17.8)	107 (25.2)	0.54 (0.21-1.36)	 
 	 			 
Stage	 			0.0962
0	10 (22.2)	175 (41.3)	1.0 (ref)	 
I	21 (46.7)	142 (33.5)	2.59 (1.18-5.67)	 
II	5 (11.1)	33 (7.8)	2.65 (0.85-8.26)	 




1	7 (15.6)	60 (14.2)	1.0 (ref)	 
2	10 (22.2)	76 (17.9)	1.13 (0.41-3.14)	 




No 	36 (80.0)	369 (87.0)	1.0 (ref)	 
Yes	 9 (20.0)	48 (11.3)	1.92 (0.87-4.23)	 
Vital Status	 			0.6605
Alive	28 (84.4)	368 (86.8)	1.0 (ref)	 
Dead	56 (13.2)	56 (13.2)	1.21 (0.52-2.84)	 
 	 			 
Histology				0.9859 
Squamous	29 (64.4)	283 (66.8)	1.0 (ref)	 
Adenocarcinoma	10 (22.2)	92 (21.7)	1.06 (0.50-2.26)	 
All other specified	4 (8.9)	40 (9.4)	0.98 (0.33-2.92)	 

None of the variables for comparison reached significant differences between the participants and non-participant women.  Analysis showed that cervical, vulvar, and vaginal cancer patients were similar all factors assessed: age, race, BMI, postmenopausal status, smoking status, alcohol use, pregnancy and birth histories, family cancer history, marital status, year of diagnosis, stage, grade, histology, recurrence, and vital status.  The two sample t-test analysis showed that participants and non-participants did not differ with respect to age (mean=54.6, 95% confidence limits=49.6-59.6 vs. mean=51.9, 95% confidence limits=50-3-53.6; p=0.3206) or BMI (mean=29.7, 95% confidence limits=27.2-32.1 vs. mean=29.4, 95% confidence limits=28.6-30.3; p=0.8726).  There were slightly higher percentages of women participating in the 45-54 (10 (22.2%) vs. 78 (18.4%) and 55-64 (11 (24.4%) vs. 64 (15.1%)) age groups, however these differences among age groups were not significant in chi-square analysis.    
In the univariate analysis, several covariates were shown to be associated with survival (p ≤ 0.1): age, stage, histology, marital status, and menopausal status.  Multivariate analysis revealed that stage was significantly associated with survival (p ≤ 0.05) (Table 13).  No significant interactions were observed.
No variables were found to reach statistical significance for logistic regression models testing the association of covariates with participation.   
Table 13. Predictors of cervical, vulvar, and vaginal cancer mortality












Participants in the biorepository were more likely to be older, postmenopausal, and white compared to non-participants.  For all gynecologic cancers, both the two sample t-test and chi-square analysis showed significant differences in the age, race and menopausal status for participants and non-participants.  With respect to recruitment, the year of diagnosis and primary location of cancer differs significantly between the participant and non-participant group.  These differences in year of diagnosis and primary location are reflective of the internal improvements to recruiting procedures and the prioritized collection of endometrial and ovarian biospecimens, the two most common gynecologic malignances, for clinical research.    The differences in the year of diagnosis indicate that, overall, recruitment was increasing with time while the cancer diagnoses in the MWH population as a whole remained stable.  These increases in patient participation are indicative of improvements to recruiting strategy and protocol, investigator effort, and dedicated staff.  
Kaplan-Meier analysis and log-rank tests revealed no statistically significant differences between the participant and non-participant groups for either recurrences or survival.  These results are expected as participants receive standard clinical care for their cancer diagnosis.  These findings indicate that disease severity does not have an effect on participation.   Cox proportional-hazards regression has shown that participation status does not have any overall effect on survival.  The covariates that did affect survival in each cancer group were age and disease severity (grade, stage and/or histology).  These results indicate that the participants’ overall survival is in line with that of the general gynecologic cancer population at MWH.
With endometrial cancer patients, race and BMI were found to differ significantly between participants and non-participants.  This disparity in participation may be indicative of the differing perceptions of clinical research between races or barriers to recruitment (Smith et al, 2007).  Overall, black women do make up a smaller percentage of the population of women seen at MWH.  MWH is located in Allegheny County, serving a patient population that includes individuals from a wider geographic area who come to this center for gynecologic care.  The United States census data for 2011 reports that Allegheny County’s population is 81.8% white and 13.3% black (US Census Bureau, 2013).  The disparity in race reported in the cancer registry patients may be indicative of greater issues related to access to care or patient education regarding early detection and screening methods.  Further investigation is needed to determine the extent of this disparity and what factors may be related.
Endometrial patients participating in the biorepository tended to have larger BMIs.  Obesity is a known risk factor for endometrial cancer and is a factor of great interest to research in this disease.  An emphasis on approaching patients with higher BMIs, whether intentional or not, may be occurring; this may explain the differences between the participant and non-participant groups.  To maintain the representativeness of the biorepository, researchers should consider what role, if any, patient BMI should play in the enrollment process.
Vital status was significantly higher in the participant group compared to non-participants among endometrial cancer patients.  The differences in vital status may be reflective of the higher participation of Stage I patients (72.5% vs. 65.2%), as no other differences were noted among grade or histology between the participant and non-participant groups.
In the ovarian cancer patients, two sample t-test results showed that participants (mean=59.0) were significantly older than non-participants (mean=56.0) (p=0.0367).  Though the difference was significant, the mean values of each group only differed by three years.  Histological differences in the ovarian cancer participants and non-participants were revealed. Clear cell and serous differentiations were higher in the participant group, while the endometrioid differentiation was lower comparatively.  Given that definitive cancer histology may not always be obtained via biopsy prior to surgery (and the consent process), the precise reason why these histological differences exist is unknown. 
The analysis of all variables for cervical, vulvar, and vaginal cancer patients showed that the participant and non-participant groups are indeed similar.  Overall, the participant and non-participant groups are similar in a number of factors that could be of concern for potential confounding in future studies.  Women in the biorepository are representative in many of the disease characteristics such as stage, grade, histology, recurrence, and survival.  The participants are similar to a number of social and health history characteristics.  Known primary risk factors for gynecologic cancers, such as pregnancy and birth history, smoking history, and family cancer are comparable between the participant and non-participant groups.

4.2	Clinical research Participants
The goal of a biorepository is to create a resource to appropriately model the population of study.  For the greatest generalizability, patients from all age ranges, races, socioeconomic backgrounds, pathologies, and clinical progressions of disease should be included.  With a greater diversity within the repository, researchers can study the population as a whole or focus on specific sub-populations.  A comprehensive and inclusive data bank and biorepository would be able to provide researchers with the required data and specimens for studies, having the statistical power to find meaningful results.  
The literature does not have specific information on cancer tissue repository participation rates; however rates for cancer clinical trial participation are less than 5% (Elting et al, 2006).  It has also been established that older adults are consistently under-represented in cancer registration trials (Scher and Hurria, 2012).  Unlike clinical trials, the MWH data bank and repository does not have exclusion criteria.  Women undergoing surgery for a gynecologic cancer, benign gynecologic condition or prophylactic oophorectomy are considered eligible for enrollment.  Women who elect to participate do not undergo any investigational or additional treatments; they are receiving standard care for their cancer.  Given this information, the one of the greatest barriers to patient enrollment is with the consent process.  
Numerous studies have been done to assess the impact and importance of the informed consent process for prospective study participants.  The timing and introduction of consent can play an important role in recruitment.  In one study, it was found that the greatest patient response occurred between 1 and 30 days following diagnosis (Gerber et al, 2012).  The authors propose that this increased response could be due to patient interest in the disease and that patient has had time to process information about diagnosis.  Another study evaluates the importance of the person obtaining consent in the process of study enrollment.  The authors have found increased participation is associated with both experience and with a gender-discordance between the person obtaining consent and potential participant (Rasco et al, 2009).  Specific to biorepositories, a study assessing the informed consent process has found that prospective participants were likely to decline participation primarily due to a lack of trust in the researchers (Beskow and Dean, 2008).
4.3	Recommendations for Patient Recruitment
Concerted effort on the part of physicians and research staff is required to approach all eligible patients for consent.  It is imperative to determine why individuals are not consenting for participation in the biorepository.  Are these patients simply not approached; is it a matter of inappropriate timing or staffing capabilities?  Is it a matter of the consent form?  Revisions to the consent form may increase participation of black women in the biorepository.  Studies have shown that recruitment may increase with culturally appropriate education and outreach for clinical research (Smith et al, 2007).   
It may be worth including a follow-up survey in the consent process to collect information on what motivated patients to participate.  It would be beneficial for research staff better understand what factors play a role in patient’s decision to enroll.  
There is potential to seek out patients who may be of research interest to the investigator.  Research staff and personnel must determine set criteria for approaching patients if the intention is to create a truly representative sample of the gynecologic cancer population at MWH.  

4.4	Conclusions
In comparing all gynecologic cancers, participants were more likely to be white, older, and postmenopausal than non-participants.  Most notably, endometrial cancer participants tended to have a higher BMI and ovarian cancer participants were found to be significantly older than non-participants.  Because these are known risk factors for their respective cancers, efforts should be made to control for any selective patient recruitment procedures.  The analysis of the gynecologic cancer primary tumor locations (endometrial, ovarian and cervical, vulvar, and vaginal) groups does indicated that despite these differences, the biorepository is a representative of disease, social, demographic, and reproductive history characteristics.  
The recurrence and survival results from Kaplan-Meier analysis showed that participants and non-participants are similar in the disease progression and survival; no advantages or disadvantages are conferred through participation.  
This analysis does reveal that researchers should assess the criteria used for patient recruitment, particularly age, BMI and race.  Increasing patient participation in the biorepository and data bank will increase representativeness and provide researchers with a robust collection of samples for future research projects.  
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Figure 2. Multivariate logistic regression ovarian results: odds ratios


Endometrioid

Mucinous

Clear Cell

Other

Table 11. continued



	39


